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Background: Depression is a high prevalence disorder, displaying high rates of lifetime incidence, early age onset,
high chronicity, and role impairment. In Ireland 12-month prevalence of depression has been reported to be 10.3%.
A large percentage of affected individuals have no medical diagnosis nor seek treatment. Cognitive Behavior
Therapy (CBT) has established itself as an option for the treatment of depression. Many Irish adults with depression
find it difficult to access evidence-based CBT, this is due to several factors, like stigma and costs. However,
systematic factors including the shortage of trained professionals and the relative underdevelopment of services
also make access difficult.
Stepped-care can increase access to evidence-based CBT. One option is tailored internet-delivered treatment
programs. Preliminary research from Ireland needs now to include large-scale studies on effectiveness. Thus the
current study seeks to examine the potential of an internet-delivered low-intensity treatment for symptoms of
depression in an Irish adult community sample.
Method/Design: The study is a randomized controlled trial of an online CBT (iCBT) program for the treatment of
adults with depressive symptoms. The trial will include an active treatment group and a waiting-list control group.
The active condition will consist of 8 weekly modules of iCBT, with post-session feedback support. Participants in
the waiting list will receive access to the treatment at week 8. Participants will complete the Beck Depression
Inventory (BDI-II) and eligibility criteria will also apply. Primary outcomes are depressive symptoms. Secondary
outcomes include quality of life indicators, significant events and satisfaction with online treatment. Data will be
collected at baseline and at post-treatment, week 8, and at follow-up week 20 (3-months) and week 32 (6-months).
Analysis will be conducted on the intention-to-treat basis.
Discussion: The study seeks to evaluate the effectiveness of an online delivered treatment for depression in a
community sample of Irish adults with symptoms of depression. The study will be a first contribution and
depending on the sample recruited the results may be generalizable to people with similar difficulties in Ireland
and may therefore give insight into the potential of low-intensity interventions for Irish people with depressive
symptoms.
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Depression has been ranked high among the leading
causes of disease burden throughout the world [1], dis-
playing high rates of lifetime incidence, early age onset,
high chronicity, and role impairment [2]. Twelve-month
prevalence rates for depression in the U.S. have been
estimated at 6.6% [3], and in Europe 8.5% [4]. In Ireland
12-month prevalence of depression as measured against
DSM-IV criteria has been reported to be 10.3% [4].
Studies have reported higher rates for women than for
men, in Europe 12-month prevalence has been reported
at 10.5% for women and 6.61% for men [4]. Another
European study that examined prevalence for older
adults (65+) reported an overall 12-month prevalence
rate of 12.3% [5]. The study highlighted the traditional
gender divide with women (14.1%) reporting a higher
prevalence of depression than men (8.6%) [5].
Epidemological studies have highlighted the occur-
rence of depression in younger age groups. A review
of the literature posits the peak years for onset to be
between 15–29 years [6]. Prevalence rates and gender
differences are relatively constant across the adult life-
span and given the earlier age onset would suggest
that lifetime prevalence will be higher in the future for
younger cohorts [6].
Depression exacts significant economic, personal,
intra-personal and societal costs. The economic costs
alone are justification for accurately understanding and
treating depression in individuals [2,7,8]. Depressive
disorders are associated with losses in quality of life
and increased mortality rates [9,10].
Treating depression
The aetiology of depression is dependent on the individ-
ual and their biological and psychosocial predisposition.
The relative importance of these factors vary across indi-
viduals. The current biologic understanding of depression
posits that many aspects of depression can be understood
in terms of dysregulation of the Central Nervous System
(CNS) responses to stress and naturally dysregulation
is influenced by a wide range of moderating variables
such as genetics, age, sex, and developmental history.
Science has been successful in identifying key neuro-
biological processes and developing medications to
compensate for dysregulation in the CNS.
Depression can be treated successfully using antide-
pressants, but relapse is high following cessation, and
many patients prefer psychological therapies [11], which
have proved equally as effective as antidepressants [12]. By
far the most extensively researched is cognitive-behavior
therapy (CBT) [13]. CBT has established itself as an op-
tion for the treatment of depression, for post-treatment
gains and also for maintaining gains and preventing future
relapses and recurrences [14].CBT is an amalgmation of cognitive science and be-
havioral science. A central construct is that of cognitive
vulnerability, where certain beliefs constitute a vulner-
ability to depression [15]. Such vulnerability has evolved
out of peoples historical experience, the consequent core
beliefs they hold about themselves, others and the world,
and their information processing capabilities that are
generally negatively attuned; each of which interact
with the other to produce a cognitive vulnerabiltiy in the
person [16]. Research has provided compelling support
for cognitive-vulnerability as theorized by Beck [17] and
demonstrates that cognitive-vulnerability increases the risk
for first episode and recurrences of depression [18].
Vulnerability is viewed as dormant until activated by
some experience that has the effect of disrupting a person’s
stability or physiological and psychological homeostasis.
The cause can be either one major event or experience, or
an accumulation of smaller experiences [19]. Collectively
they are grouped under the rubric of stress. The majority of
research investigating possible links in depression consist-
ently find a link between the experience of a stressful life
event and the onset of depression [20].
Cognitive-behavioral treatment consists of a range of
cognitive and behavioral strategies that aims to correct
distressing beliefs and thinking that occurs in informa-
tion processing with depression prone individuals, in
doing so distress is alleviated and strategies and skills
are taught to help the person cope more effectively with
life’s challenges [16]. Treatment therefore includes self-
monitoring and thought recording, behavioural activa-
tion, cognitive restructuring, challenging core beliefs,
among others.
Access to treatment
Worldwide, a large percentage of affected individuals have
no medical diagnosis nor seek treatment [21]. One study
estimated the worldwide treatment gap in depression at
56.3% [22]. Several barriers to accessing treatment exist,
such as waiting lists, lack of motivation for change, nega-
tive perception of psychological and/or drug treatments,
costs, and personal difficulty such as stigma; each can play
an important role in choosing to seek diagnosis and treat-
ment [22,23]. Of those that may seek the help they need
they are often met with a shortage of trained professionals
and consequent waiting lists, which contradicts the bene-
fits of early intervention [24].
Many in Ireland with depression find it difficult to ac-
cess appropriate and evidence-based CBT, this is due to
several factors, some of which were mentioned earlier as
barriers, but particularly in Irelands case, the shortage of
trained professionals alongside the relative underdevelop-
ment of services makes it difficult to access treatments [25].
Many Irish present their psychological difficulties, initially,
to their primary care phsician however, one survey reported
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in psychological therapies and 85% referred less than 5% of
their service users with mental health difficulties to special-
ists [26]. More recent reports also corroborate the state
of affairs where less than 20% of patients presenting with
mental health difficulties at Irish general practitioners are
in receipt of secondary specialist services [27,28].
Stepped care models of treatment
In recent years attempts to overcome barriers to access
have been addressed through the evolution of a new
understanding in mental health care that recognizes
high-intensity (e.g. face-to-face therapy) and low-intensity
(e.g. bibliotherapy) services. Low-intensity interventions
signify treatments that limit specialist therapist time,
or use this time in a cost effective manner, for example,
group treatments [29]. To increase access to evidence-
based psychological therapies it will be necessary to
develop and deploy a stepped-care model where low-
intensity interventions are provided as a first option,
before referral to high-intensity interventions. Such a
program is recommended as best-practice by the National
Institute for Health and Clinical Excellence [13] and also
advocated by the Irish health service [30]. Yet, despite the
barriers that exist for Irish people, both personal and sys-
temic, what is considered best-practice has not evolved in
Ireland. Given the continued growth in high prevalence
disorders (depression and anxiety) there is a real need
to increase access. The experience of our neighbours in
the UK through the Improving Access to Psychological
Therapies program that uses a stepped-care model, intro-
ducing both low- and high-intensity interventions, has
proven successful [31].
Delivering low-intensity interventions for depression
One of a range of low-intensity interventions is the de-
velopment and delivery of tailored treatment programs
for specific disorders using the internet, as both clinican-
guided and self-administered interventions [32]. Indeed
CBT has proved a suitable evidence-based option for inte-
gration as a low-intensity intervention within a stepped care
model [33]. More precisely, low-intensity internet-delivered
treatments for depression have established a sound base
supporting their effectiveness and efficacy [34]. In addition,
such studies for depression treatment that provide human
support yield enhanced results compared to those with
no support [34,35].
The internet offers the possibility of delivering a treatment
intervention at low cost and perhaps overcoming some of
the barriers to access mentioned earlier. The internet can
deliver treatment incrementally and in an engaging way.
Furthermore, internet penetration in Ireland is at 76.8% [36]
and it is likely that it is an attractive medium as people are
already high users of the internet and related tools.A number of small scale studies of online delivered
treatments have been experimented with in Ireland
[37,38]. There is now a need to develop larger community
based projects like those that have occurred throughout
Europe to assess the feasibility, efficacy effectiveness and
scalability of such low-intensity interventions for Ireland.
Because high-intensity interventions cannot be delivered
en-mass, Ireland, like its European neighbours, will have
to consider the implementation of stepped-care that will
include a broad range of low-intensity interventions as
first options in care.
Therefore using established CBT principles informing
skills and strategies for the management of depression in
an integrated disorder-specific treatment plan, the study
aims to deploy these using a novel computer-delivered
software platform (SilverCloud) to help demonstrate its
feasibility, efficacy and effectiveness as a low-intensity
intervention for depression treatment. The platform be-
ing used integrates a number of innovative engagement
strategies for improving the user experience: personal,
interactive, supportive and social [38]. The details of the
platform and the content of treatment are described in
more detail below.
Dropout from online treatments
Although several online studies have reported benefits
for users who have not completed the entire course of
treatment [39] it is still the case that dropout is a contin-
ued cause of concern, especially for self-administered
treatments that do not involve a therapist or other form
of support to users [40]. Information to date on reasons
for dropout is limited. Some studies have report vari-
ables such as difficulties using the computer, negative
features of the program, perceived as too demanding,
poor clinical progress, receiving alternative treatment,
feeling better, lack of time, and problems understand-
ing the computer program [34,41]. These are useful
and more indept exploration of these and other poten-
tial reasons is needed so as to inform both the develop-
ment and adequate implementation of online delivered
treatments. The SilverCloud platform that is been
used in the current study has been designed by a
multi-disciplinary team of computer scientests, clinical
personnel, and academics. It therefore includes a number
of engagement strategies for improving the user ex-
perience (personal, interactive, supportive and social)
and supporting retention.
Aware
Aware is a charity that aims to create a society where
those with depression or related mood disorders, and
their families, are understood and supported, are free
from stigma and have access to a broad range of support
options. The charity has existed since 1985 and their
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people about depression and mood disorders, their
causes and consequences. Second, to provide emo-
tional and practical support to individuals and their
families. Third, to support research into understanding
and treating depression.
They achieve their objectives through the provision of
over 2,000 face-to-face support groups nationwide that
are facilitated by trained volunteers. They have recently
started a online support group, beginning in 2011 with 5
users rising to 15 at the start of 2012. They have a low-
cost telephone line that in 2011 took over 19,000 calls,
again all manned by trained volunteers. Aware is a well
recognized and respected brand name in Ireland and
receive some government funding with 80% of their
funding raised from public donations. Their user group
is national and numbers of users high, therefore they
are well placed to collaborate in providing a low-intensity
depression treatment for the community that will include
support for participants.
Objectives of the trial
The study aims to implement and evaluate the efficacy
of an online self-administered treatment for depression,
with support, for users of the Aware Charity that have
depressive symptoms. The research questions are:
▪ First, can an online treatment for symptoms of
depression be effective as a low-intensity community-
based intervention for adult users with depression?
▪ Second, what do participants find helpful and hindering
in their online treatment for depression symptoms?
▪ Third, are participants satisfied with accessing and
using an online treatment for depression symptoms?
▪ Fourth, what are the reasons for dropout from an
online treatment?
Based on the success that has been achieved with
supported online treatments for depression [34] we
hypothesize that participants in the trial will demon-
strate significant decreases in depressive symptoms
post-intervention and a corresponding increase in
quality of life indicators.
Methods
Study design
The study is a randomized controlled trial of an internet
intervention for the treatment of depression. Participants
will be randomized into two groups: the internet-delivered
intervention with support and a waiting-list control group.
The study protocol, information on the study, informed
consent and related materials have been submitted and
approved by the ethics committee at the School of
Psychology, Trinity College Dublin (22/11/2013).Sample size
An analysis of a number of previous studies of an online
intervention for depression in the community and that
have used a CBT protocol similar to the intervention in
the current study have reported post-treatment effect
sizes averaging 1.29, and follow-up effects averaging 1.42,
based on samples ranging from 45 – 300 [39,42-48]. We
calculated power using G-Power software [49], using a
power of 0.80 and an alpha of 0.05, we would need 60
subjects in each arm of the trial to observe a moderate
(d = .50) post-treatment difference.Eligibility criteria
All adult users of Aware services will be eligible to partici-
pate. On screening participants, the following eligibility
criteria will apply:
Exclusion criteria:
Suicidal intent/ideation: score >2 on BDI-II question 9
Psychotic illness
Currently in psychological treatment for depression
On medication for less than 1 month
Alcohol or drug misuse
Previous diagnosis of an organic mental health disorder
Depression preceding or coinciding a diagnosed medical
condition
Inclusion Criteria
18 years of age
Mild to Moderate depressive symptoms (BDI-II 14–29)Recruitment
Aware is a charity that provides face-to-face, online and
phone support for people experiencing depressive
symptoms. The model is based on peer support but
their trained volunteers also incorporate evidence-based
life skills training for managing depression.
Potential participants will be able to visit a website to
receive information on the study, what will be involved
in participating, the treatment, and how to make contact
and proceed with screening. On agreeing to participate,
informed consent will be completed online and there-
after the baseline screening questionnaires.Randomization
Randomization will take place at the individual level
after the baseline screening. Computer algorithms will
determine scores on the screening questionnaires and
will automatically assign participants to one of two
groups – active intervention group or a waiting-list
control group. Participants will be immediately informed
about the randomization outcome. The randomization
procedure will be managed by a person independent of





Assessed for Eligibility (n =  )
Randomised
(n = 120)
Excluded (n =  )
Not meeting inclusion 
criteria (n =  )
Refused to participate 
(n =  )
Other reasons (n =  )
Allocated to active intervention (n = 60)
Received allocated intervention (n =  )
Did not receive intervention (n =  )
Allocated to waiting list control (n = 60)
Received allocated intervention (n =  )
Did not receive intervention (n =  )
Lost to followup (n =  )
Discontinued intervention (n =  )
Lost to followup (n =  )
Discontinued intervention (n =  )
Analysed (n =  )
Excluded from analysis (n =  )
Analsyed (n =  )
Excluded from analysis (n =  )
Figure 1 Flowchart of the study CONSORT.
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SilverCloud platform
Based on the inventive technologies that comprise the
SilverCloud platform, the program for the treatment of
depression employs several innovative engagement strat-
egies for improving the user experience, described below:
1) Personal – The user has their own secure home
page, which is about them and where they are in the
program. For example, the user can fill in a profile
with basic information about themselves. As well as
establishing a sense of ownership, this information is
also useful for the supporter, allowing them to
provide more personal feedback. The homepage is
intended to provide a reflective space; the user can
document their thoughts and feelings, and these can
be elaborated on within the journal application,
which also acts as the vehicle for therapeutic writing
exercises. The user has actions suggested to them,
and as they complete modules of the program, their
achievements are noted. Users are free to access the
modules in any order they wish, in either a linear or
non-linear manner, contributing to a sense of
empowerment. As well as the central content being
delivered, a range of satellite applications areprovided, such as a goal-setting application, which
can be used independently of the program content.
Applications are released as the user completes
modules, with the intention of maintaining engagement
by introducing new features over time and not
overwhelming the user initially. Users can also control
which applications appear on their home page.
2) Interactive – The program includes a number of
interactive elements and graphical exercises, which
are aimed at engaging users with the therapeutic
content, for example, reflecting on their own
thinking. Users also have the ability to respond to
content, indicating whether they like it, and also to
comment on it. Both exercises and comments can
be explicitly shared with the supporter. The user is
provided with immediate feedback wherever
possible; for example, when a charting exercise such
as a mood chart is completed, the application item is
graphically updated on the home page. Likewise,
items are ticked off on the to-do list when completed,
and achievements unlocked in each module summary.
3) Supportive – Each user has an assigned supporter,
who provides weekly reviews of their progress on
the program. This support is asynchronous, whereby
the supporter sets a date to review their user’s
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or contact outside this time. The supporter can
support multiple users, logging in once weekly for
instance, and reviewing the work of all their online
users within an allocated time period. Such
asynchronous online contact may be logistically
easier to implement for many services compared to
motivational interviewing and telephone support.
The system supports the exchange of messages
between the user and supporter, but goes beyond
electronic mail as the user is encouraged to share
their content (such as completed exercises and
comments) with their supporter. This shared
content allows the supporter to respond in a more
personal way and provide guidance as well as
encouragement to keep using the program.
Adherence information is also available to the
supporter, and they can keep track of the user’s
progress. This is all personally sensitive information,
and so a shared view is provided in the user
interface where they can see the supporter’s view of
their data. By making the visibility of their data to
the supporter more transparent, as well as the ability
to explicitly change the sharing status of data, the user
is provided with a greater sense of control while
facilitating a meaningful interaction with the supporter.
4) Social – While group therapy and peer group
support are well established, introducing contact
with other users within any online system raises a
number of ethical concerns regarding the possibility
for unhelpful or negative content or
communications. As a first step, the user can see
anonymous indications of other people in the
system. The intention is to reassure users that they
are not alone in experiencing difficulties and that
many other people have experienced similar
problems and overcome them. Users can respond to
content by indicating that they “like” it, and can see
how many other people liked it, helping to reduce
the sense of isolation. Other more detailed shared
content (such as tips and ideas) is subject to
supporter moderation.
Computerized cognitive-behavior therapy (iCBT) program
Mind Balance is a seven-module online CBT-based
intervention for depression, delivered on a Web 2.0
platform using media-rich interactive content. The
treatment comprises cognitive and behavioral components
including self-monitoring and thought recording, behav-
ioural activation, cognitive restructuring, and challenging
core beliefs. The structure and content of the program
modules follow evidence-based CBT principles. The
content of each module is described briefly in Table 1
below. Each module is structured in an identical wayand incorporates introductory quizzes, videos, informa-
tional content, interactive activities, as well as homework
suggestions and summaries. In addition, personal stories
and accounts from other users are incorporated into the
presentation of the material.
Waiting list control group
Participants in the waiting-list control group receive no
treatment for the duration of the first 8 weeks. At week
8 waiting-list participants will complete the primary and
secondary outcome measures (BDI-II, Sociodemographic
& History, GAD-7, WSAS and EQ-5D) and will be given
access to the program for 8 weeks with support from a
trained volunteer.
Support during treatment
Each participant will be assigned a supporter who will
monitor their progress throughout the trial. Once a
participant is assigned to the active treatment condition at
their first login there will be a message from their
supporter. This is a standard message addressed to the
participant, welcoming them to the program, highlighting
aspects of the program, encouraging them in the use of
the program, and letting them know that each week their
supporter will login and review their progress, leaving
feedback for them and responding to the work they have
completed. All supporters are presently trained supporters
working with Aware. In addition, they will receive further
training in the SliverCloud platform and how to deliver
feedback (2 evenings 6–9 pm and one full day 10-5 pm).
Each supporter will be assigned 8 participants to provide
post-session feedback of between 10–15 minutes per
participant per session. As part of the online program,
a dashboard interface will be provided to supporters
that will give them an overview of their participant’s
level of engagement with the program content. The
supporters will respond to the work of their partici-
pants from session to session.
Supporters will form groups of five and have a senior
supporter as a mentor. The senior supporters are volun-
teers with many years experience and have responsibil-
ity for inducting and training other volunteers within
the Aware charity. Supporters will meet on a weekly basis
for guidance on how support is delivered and discuss any
difficulties. In addition, supporters will meet monthly with
two senior trainers at Aware to review guidance and
process case examples of feedback.
Assessments
Participants will be assessed at baseline, posttreatment,
and at 3 and 6 months follow-up. The study variables
assessed are summerized in Table 2.
At baseline, assessments include the Beck Depression
Inventory-II (BDI-II), Sociodemographic & History
Table 1 Mind Balance: description of module content
Module name Brief description
Getting Started Outlines the basic premise of CBT, some information about depression, and introduces some of the key
ideas of Mind Balance. Users are encouraged to begin to chart their own current difficulties with depression.
Tune In I: Getting to Grips with Mood The focus in this module is on mood monitoring and emotional literacy. Users can explore different
aspects of emotions, physical reactions, action and inaction, and how they are related.
Tune in II: Spotting Thoughts This module focuses on noting and tracking thoughts. Users can explore the connection between
their cognitions and their mood, and record them graphically.
Change It I: Boosting Behaviour This module focuses on behavioural change as a way to improve mood. Ideas about behavioural activation
are included, and users can plan and record activities, and chart their relationship with their mood.
Change It II: Challenge Your Thoughts This module supports users to challenge distorted or overly negative thinking patterns, with thought
records, as well as helpful coping thoughts
Change It III: Core Beliefs This module outlines the role that deeply-held core beliefs can play in mood and depression. Users can
use a range of interactive activities to identify, challenge and balance any unhelpful core beliefs.
Bringing It All Together In this final module, users are encouraged to bring together all the skills and ideas they have gathered
so far, note their personal warning signs, and make a plan for staying well.
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and the Work and Social Adjustment Scale (WSAS), and
EuroQol 5D (EQ-5D) will be completed for screening pur-
poses. Thereafter the BDI-II, GAD-7, EQ-5D and WSAS
will be completed at the end of treatment, week 8, and at
follow-up, week 20 (3-months) and week 32 (6-months).
After each session participants will be asked to complete
the Helpful Aspects of Treatment Form (HAT). The meas-




Sociodemographic Information & History Questionnaire
will be developed based on a previous version [39] and
will collect demographic details on the participants. It
collects data on previous diagnosis of anxiety disorders
and length of time that one is experiencing depression
symptoms. It will collect data on participant’s experience
of counseling/therapy and medication for depression.
Data is collected on whether one has a previous diagnosis
of an organic mental health disorder such as schizophre-
nia, psychosis, bipolar disorder. In addition, it containsTable 2 Study measures to be used
Measure Assessment
Beck Depression Inventory-II (BDI-II) Depression sympto
Generalized Anxiety Disorder-7 (GAD-7) Anxiety symptoms
Sociodemographic & History Questionnaire Gender, age, marit
occupation, socioe
Work and Social Adjustment Scale (WSAS) Work and Social A
EuroQol 5D (EQ-5D) Quality of Life
Engagement and Usage data Engagement and u
Satisfaction with Treatment (SAT) Satisfaction with th
Helpful and Hindering Aspects of Treatment (HAT) Helpful and hinderitems related to co-morbidity of depression with presence
of psychosis, alcohol and drug misuse, and/or any recent
medical diagnosis.
Primary outcome measure
The Beck Depression Inventory (BDI-II) [50] The 21-item
Beck Depression Inventory – Second Edition (BDI-II) is a
widely used questionnaire developed for the assessment of
depressive symptoms that correspond to the criteria for de-
pressive disorder diagnosis as outlined in The American
Psychiatric Associations Diagnostic and Statistical Manual
of Mental Disorders–Fourth Edition (DSM-IV) [51]. Each
item is scored on a scale from 0 to 3. The BDI-II manual
states that a cut score of 17 has yielded a 93% specificity
and 18% sensitivity for the presence of major depression
(Beck et al., [50]). The scale designates levels of severity,
Minimal (0–13); Mild (14–19); Moderate (20–28); and
Severe (29–63) [50].
The BDI-II has been found to have excellent internal
consistency and test–retest reliability with a diverse range
of samples [50,52,53]. The BDI-II has demonstrated good
convergent validity with other measures of depression
among clinical and nonclinical adult samples [54].Time of assessment
ms Baseline, posttreatment and follow-up
Baseline, posttreatment and follow-up
al status, education,
conomic status, and history
Baseline
djustment scale Baseline, posttreatment and follow-up
Baseline, Posttreatment and follow-up
sage Continuous
erapy Posttreatment
ing aspects of therapy After each session
Richards et al. BMC Psychiatry 2014, 14:147 Page 8 of 11
http://www.biomedcentral.com/1471-244X/14/147Secondary outcomes
General Anxiety Disorder (GAD-7) [55] comprises 7 items
measuring symptoms and severity of GAD based on the
DSM-IV diagnostic criteria for GAD. The GAD-7 has good
internal consistency (.89) and good convergent validity with
other anxiety scales [56]. Increasing scores indicating greater
severity of symptoms [57]. The GAD-7 is increasingly used
in large-scale studies as a generic measure of changes in
anxiety symptomatology, using a cut-off score of 8 [31,58].
Work and Social Adjustment (WSAS) [59] The WSAS
is a simple, reliable and valid measure of impaired func-
tioning. It is a simple 5-item self-report measure which
provides an experiential impact of a disorder from the
patient’s point of view. It looks at how the disorder im-
pairs the patient’s ability to function day to day on five
dimensions: work, social life, home life, private life and
close relationships.
EuroQol 5D (EQ-5D) [60]. Is a generic instrument of
health-related quality of life: Part 1 records self-reported
problems in each of five domains: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. Each
domain is divided into three levels of severity corre-
sponding to no problems, some problems, and extreme
problems, which allows obtaining a population-based
preference score or societal index (SI). Part 2 records the
subject’s self-assessed health on a Visual Analogue Scale
(VAS), a 10 cm vertical line on which the best and worst
imaginable health states score 100 and 0, respectively.
Other measures
Helpful Aspects of Therapy Form (HAT) [61,62] is an
instrument that assesses the most helpful and hindering
events in the therapy. The user is asked to describe in
their own words whether there was anything particularly
helpful or hindering in the session. Participants are asked
to describe any event, anything they engaged with in the
session that was helpful or hindering for them.
Satisfaction with Treatment (SAT) [39] At post-
treatment participants will be asked to complete a
satisfaction with treatment measure. The measure is
based on a Net Promotoer Score: which is a management
tool that can be used to gauge the loyalty of a firm’s cus-
tomer relationships. It serves as an alternative to traditional
customer satisfaction; it includes one question: How likely
is it that you would recommend this treatment to a friend
or colleague? Descriptive statistics will be used to report on
the data from the other quantitative questions on the SAT
measure. The satisfaction measure will also contain two
questions asking to describe what they most liked and least
liked about the online treatment.
Pre-treatment and during treatment dropout questionnaires
Two simple questions will be developed for the study,
one asking about the reasons for deciding to dropoutwithout beginning treatment and the second asking about
the reasons for dropping out during treatment. The link
for each of these will be contained in the appropriate
emails that clinicians send to their respective participants,
following the protocol: Pre-treatment dropout - after one
week the clinician can send the questionnaire by e-mail.
Participants discontinue treatment, after one missed ses-
sions the clinican should send a reminder message to the
participant by email. If after one further week the passrti-
cipant has not responded the clinician can send the ques-
tionnaire asking about the reasons for dropout.
Engagement and usage measures
The online system will collect anonymized descriptive
information relating to engagement and usage. Data col-
lected will include the number of sessions completed; mean
time spent on the program, average number of sessions per
user, and average length of a session. A session is defined as
an instance where a user logs on to the system. Session
time estimation will always be an imperfect calculation, as
users may be interrupted or take breaks within a session,
and may not formally log out of the system. All user activity
within the system such as reading a content page, saving a
journal entry, or updating an activity, is logged with a time
stamp. Starting with the log entry of the user logging on,
the total time is calculated by adding up the time that
elapses between each subsequent log record (in the same
manner as popular web analytics software). On its own, this
will yield a result vulnerable to overestimation of session
time. To avoid counting periods where the user is not ac-
tively engaged with the system, any interactions taking lon-
ger than 30 minutes are counted as 1 minute. Any period
of inactivity longer than 3 hours will start the count on a
new session, rather than extending the time of the current
session. Use of different program components will be mea-
sured. Data related to supporter reviews will be collected.
Ethical considerations
Informed consent will be obtained from each participant
before randomization. Before consent participants will
be made fully aware of what is involved in participating
and especially the importance of the waiting-list control
group. They will be familiar with the aims and objectives
of the study and why the study is important. They will
also be informed that they will be participating voluntar-
ily and if they so wish can withdraw at any time. At
baseline if participants are excluded on the basis of the
established exclusion criteria they will be referred to
other appropriate sources of support such as Aware Charity
telephone line and e-mail support.
Planned statistical analysis
The analyses will be based on the intention-to-treat
principle, including those who began treatment and
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ance. Effects will be tested at the 0.05 level. All analyses will
be carried out using SPSS. Baseline differences in demo-
graphic and clinical characteristics will be investigated
using ANOVA. To assess for significant changes over
time, repeated measures ANOVAs will be performed
for the primary outcome measure for depression (BDI-II).
In case of significant time x group interactions, contrasts
will be conducted comparing changes from baseline to
post-treatment for each group separately. Further any
relationships between baseline sociodemographic data
and outcomes on the primary outcome measure will be
assessed. Repeated measures ANOVAs will also be used
to assess any changes over time for secondary outcomes
(GAD-7, EQ-5D and WSAS).
The magnitude of the within-group effects of each of
the interventions (Cohen’s d) will be calculated using the
pooled standard deviation. The magnitude of between-
group effects will be established by subtracting the
Cohen’s d statistic for the two groups [63]. For Cohen’s
d an effect size of 0.2 to 0.3 can be considered a small
effect, around 0.5 a medium effect and 0.8 upwards, a
large effect [64].
Analysis will be made to determine the proportion of
participants who make clinically meaningful change at
end of treatment and at follow-up. An assessment of
remission will be made using pre-treatment compared
to post-treatment and follow-up scores on the primary
outcome measure (BDI-II) and also for the secondary
outcomes (GAD-7). The assessment of remission will
consider the following cut-off scores for the primary
outcome measure BDI-II score of <14 [50], and GAD-7
total score ≤8 [57] and and WSAS <10 [59]. In addition,
using the post-treatment scores for depression (BDI-II)
and anxiety (GAD-7) and dividing these with their pre-
treatment scores a calculation of relative risk of depression
and anxiety can be made [58].
An index of recovery will be established by identifying the
percentage of participants whom achieved a 50% reduction
in pre-treatment compared to post-treatment score on
BDI-II and GAD-7 [58]. In addition we will also calculate
the number of reliably changed and recovered participants
using Jacobson and Truax’s [65] criteria.
To analyse the HAT data we will use the descriptive
and interpretative framework described by Elliott and
Timulak [66]. Participants’ responses will be consid-
ered within domains of helpful and non-helpful events
and impacts. Firstly, individual units of text that could
stand meaningfully out of their context will be identified.
Next each of these will be organized into domains of help-
ful events and helpful impacts. Similar events and impacts
will be grouped into categories, which will be then finalized
and suitably named and defined. The process is organic,
involving constant reference to the source data [67].Descriptive statistics will report on the results from
the quantitative questions on satisfaction. The SAT data
collected from the two open questions will be analysed
qualitatively following the descriptive and interpretative
framework described by Elliott and Timulak [64,68].
Similarly, data from droput pre-treatment and during
treatment will be analysed qualitatively.
Discussion
The study seeks to evaluate the efficacy and effectiveness
of an online delivered treatment for depressive symptoms
in a sample of adult users of a charity service. The study
will be a first contribution to the potential for An online
low-intensity intervention to demonstrate decreases in
depressive symptoms for participants as compared to
the waiting-list control. The study will be a contribution
to the already established work in online treatments for
depression worldwide.
The primary outcome measure (BDI-II) that will assess
depressive symptoms is a well established measure and
has been used in other trials of internet-delivered treat-
ments. The secondary outcome measures (GAD-7, HAT,
SAT, EQ-5D, WSAS) included in the study will contrib-
ute to what participants find satisfying with online treat-
ments and further will detail what in-session events and
their impacts participants report as being helpful or
hindering in their online treatments. The WSAS will
yield information on improvements in quality of life
for participants, as will the EQ-5D. The GAD-7 will shed
light on the prevalence of comorbid anxiety disorder that
occurs with depression in the sample.
It is hoped that with the inclusion of pre-treatment
and during treatment dropout questionnaires that the
study can make a contribution to developing a better
understanding of the reasons for dropout in online
treatments.
Depending on the sample recruited the results may be
generalizable to people with mild to moderate symptoms
of depression in Ireland and may therefore give insight
into the potential of low-intensity interventions for Irish
people with depressive symptoms. The internet-based
intervention is probably most interesting for people who
look for alternative healthcare because the possibility of
accessing traditional services is near impossible, prohibi-
tive due to waiting lists, costs, and personal stigma.
While the study will not include an official diagnosis
of participants, it does include established measures that
will gather valuable data on participants that can allow
us to begin to build a picture of the relevance of iCBT
treatments for depression in Ireland.
Trial status
Currently we are preparing all necessary materials for
the launch of the trial in January 2014.
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